News

Reshaping of Medivir completed

Tuesday 10 January 2017
Country
Sweden

With the completion of a purchase and a sale, Medivir AB has transformed itself into a pure product development company with 75% of its research budget allocated to clinical trials instead of 40% previously.

Enterome starts trial of microbiome drug

Sunday 8 January 2017
Country
France

Enterome SA has started a Phase 1 study of its lead small molecule drug directed at the gut microbiome. The candidate drug targets the FimH protein as a means of blocking inflammation in Crohn’s disease.

Illumina spin-out plans to raise $1 billion for cancer test

Saturday 7 January 2017
Country
United States

In one of the strongest signs yet that cancer detection is becoming a mainstream investment, Illumina Inc said it has received “indications of interest” from undisclosed investors to supply $1 billion in venture capital to Grail Inc, its diagnostics’ spinout.

NeRRe gets capital for early-stage drugs

Friday 6 January 2017
Country
United Kingdom

NeRRe Therapeutics Ltd, a 2012 spin-out of GlaxoSmithKline Plc, has raised £23 million in an oversubscribed Series B financing round to advance its portfolio of neurokinin receptor antagonists. The lead product is being developed for a chronic respiratory condition.

RondinX launches microbiome analysis tool

Friday 6 January 2017
Country
Israel

RondinX, a start-up company based in Tel Aviv, Israel, has launched a tool that it says will enable researchers to analyse the human microbiome from single metagenomic samples. This is expected to give a boost to drug development.

Versant poised for biotech investments

Wednesday 4 January 2017
Country
United States

Versant Ventures has raised $400 million for its sixth healthcare fund – enough capital to help finance up to 25 biotechnology companies across the US, Canada and Europe. The new fund, Versant Venture Capital VI, is expected to make its first investment before the end of March.

Chiesi and Aptuit to research fibrosis

Wednesday 4 January 2017
Country
Italy

Chiesi Farmaceutici SpA, a family-controlled pharmaceutical company based in Parma, Italy, has teamed up with Aptuit LLC, a US contract research organisation, to discover new compounds for idiopathic pulmonary fibrosis (IPF), a serious, chronic lung disease.

Remission reported for aggressive brain tumours

Thursday 29 December 2016
Country
United States

A 50-year old patient with recurrent cancer involving tumours in both the brain and spinal cord has been treated with a chimeric antigen receptor (CAR) T cell therapy targeting an antigen that is overexpressed in a majority of glioblastomas.

UK microbiome company launched

Thursday 29 December 2016
Country
United Kingdom

Microbiotica Ltd, a spin-out of the Wellcome Trust Sanger Institute, has raised £8 million in start-up capital to research new medicines derived from the microbiome, the collection of bacteria in the human gut that helps regulate human health and disease.

FDA approves drug for muscle disorder

Tuesday 27 December 2016
Country
United States

The Food and Drug Administration (FDA) has given its first approval to a drug for spinal muscular atrophy, a hereditary disease that causes weakness and muscle wasting. The drug, Spinraza (nusinersen), is an antisense oligonucleotide that binds to RNA in order to regulate gene expression.